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Abstract
In this column, we provide a brief review of important papers recently published that relate to the ﬁeld of Emergency
Medicine. The goal is to provide the busy clinician a bullet-like summary of the study, focusing on the research
question, methods, results, limitations and bottom line interpretation.
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I

n this quarter's column, we provide a brief review of important papers published in the last
year that relate to the ﬁeld of Emergency Medicine.
Our goal is to provide busy clinicians a concise
summary of the study, focusing on the research
question, methods, results, limitations and bottom
line interpretation. There are 18 papers reviewed
herein.
1. Topic: Trauma

Question: Is CT angiography (CTA) adequately
sensitive to rule out aerodigestive injuries (ADI) in
penetrating neck trauma?
Study: Paladino L, et al. Computed tomography
angiography for aerodigestive injuries in penetrating neck trauma: A systematic review. Acad
Emerg Med. 2021 May 21.
Methods: This was a systematic review of published studies evaluating the sensitivity and speciﬁcity of CTA for detecting ADI.
Results: 1242 citations were identiﬁed. Ultimately
7 studies met inclusion criteria. There was an ADI
prevalence of 13.4%. CTA for ADI had a sensitivity
of 92%, and speciﬁcity of 88%. Of the 26 identiﬁed
esophageal injuries, ﬁve (19%) were initially missed
by CTA.
Limitations: There were signiﬁcant variations in
the quality of studies, and only 7 studies met

criteria for inclusion. Risk of bias and lack of
blinding to outcomes also may affect the validity of
results.
Bottom Line: CTA appears to be insufﬁciently
sensitive to reliably exclude esophageal injuries in
penetrating neck trauma. Additional diagnostic
modalities (swallowing studies, endoscopy, or surgical exploration) should be utilized to safely
exclude esophageal injury. These injuries have high
morbidity and delayed diagnosis can lead to serious
complications. Further evaluation should strongly
be considered when the mechanism suggests the
possibility of ADI.
2. Topic: COVID
Question: What is the incidence of myocarditis
following vaccination for COVID-19?
Study: Simone A, et al. Acute Myocarditis Following
COVID-19 mRNA Vaccination in Adults Aged
18 Years or Older. JAMA Intern Med. 2021 Oct 4.
Methods: This was a population cohort based
study performed within the Kaiser Permanente
Southern California healthcare system of adults 18
years of age and older who received at least one
dose of the Pﬁzer or Moderna mRNA vaccine between December 14, 2020, and July 20, 2021. Potential cases of post-vaccine myocarditis were
identiﬁed based on reports from clinicians and by
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record review of patients hospitalized within 10
days of vaccine administration with a discharge
diagnosis of myocarditis. The incidence of postvaccine cases was compared with the incidence of
myocarditis in unexposed individuals between
December 14, 2020, and July 20, 2021 and with
vaccinated individuals during a 10-day period 1 year
prior to vaccination.
Results: 2,392,924 vaccine exposed individuals
were compared with 1,577,741 non-exposed individuals. The groups were relatively similar in
regards to sex and ethnicity. There were 15 cases
of myocarditis in the vaccinated group, with an
incidence of approximately 5.8 cases per million
during the 10 day period following vaccination
after receiving two vaccine doses. All cases were
observed in men with a median age of 25 years.
Estimated 10-day incidence in non-exposed individuals was 2.2 cases per million, with 52% of
cases occurring in men, with a median age of 52
years. An analysis using vaccinated individuals as
their own controls yielded similar results. No
individuals required ICU admission and symptoms resolved in all cases with conservative
measures.
Limitations: This is observational data, therefore a
causal link between vaccination and myocarditis can
not be established using this data. There may be
reporting bias, and a more extensive cardiac workup
may have been performed in patients presenting
with chest pain after vaccination than in the control
group.
Bottom Line: The incidence of post-vaccination
myocarditis is very low, but signiﬁcantly higher than
in non-exposed individuals. It was observed to be
much more common (universally in this cohort) in
young males. There were no cases requiring intensive care treatment and all observed cases resolved
with supportive care and without apparent longterm sequelae.
3. Topic: Electrolytes
Question: What is the ideal emergency department (ED) management of hyperkalemia?
Study: Raﬁque Z, et al. Hyperkalemia management in the emergency department: An expert
panel consensus. JACEP Open. 2021; 2:e12572.
Methods: This is a review of the best available
evidence and consensus expert opinion on the
management of hyperkalemia in patients presenting
to the ED. This panel was sponsored by the American College of Emergency Physicians (ACEP) with
the goal of creating a consensus guide for the
management of acute hyperkalemia.
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Results: The authors propose a stepwise algorithm for the management of hyperkalemia, which
they deﬁne as Kþ > 5.5 mEq/L and symptoms of
acute illness).
Step 1. Determine if the Kþ value is correct and is
not due to pseudo or spurious hyperkalemia.
Step 2. Evaluate for cardiac involvement with electrocardiography and give calcium if ECG changes
are present.
Step 3. Treat appropriately based on the Kþ level
and clinical condition.
Step 4. Reassess Kþ level in 2e4 h.
Step 5. Determine disposition. Select patients may
be suitable for discharge, but most will need to be
admitted for monitoring and some will need ICU
level of care.
Limitations: There is a lack of strong published
literature to support many of these recommendations and even experts vary widely in their views on
hyperkalemia management.
Bottom Line: This document is an attempt by ACEP
to standardize management of hyperkalemia in the
emergency department. It serves as a reasonable
framework for evaluation and treatment of these
patients and is as evidence-based as we are likely to
get on this topic. Some recommendations may not
be practical at your institution, and it is obviously
important to discuss with nephrology and use
shared decision making in many cases, especially
when dialysis is recommended.
4. Topic: Cardiac Arrest
Question: Does the use of methylprednisolone or
vasopressin for in-hospital cardiac arrest affect rates
of ROSC or favorable neurologic outcomes?
Study: Granfeldt A, et al. Effect of Vasopressin and
Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital
Cardiac Arrest: A Randomized Clinical Trial. JAMA.
2021 Sep 29:e2116628. doi: 10.1001/jama.2021.16628.
Epub ahead of print.
Methods: Multicenter placebo controlled randomized trial of in-hospital cardiac arrest patients
who either received usual care or usual
care þ methylprednisolone/vasopressin. Primary
outcome was time to return of spontaneous circulation. Secondary outcomes included survival and
favorable neurologic outcomes at 30 and 90 days.
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Results: Among 512 patients who were randomized,
501 met all inclusion and no exclusion criteria and
were included in the analysis. 100 of 237 patients
(42%) in the vasopressin and methylprednisolone
group and 86 of 264 patients (33%) in the placebo
group achieved return of spontaneous circulation
(risk ratio, 1.30 [95% CI, 1.03e1.63]; risk difference,
9.6% [95% CI, 1.1%e18.0%]; P ¼ 0.03). At 30 days, 23
patients (9.7%) in the intervention group and 31
patients (12%) in the placebo group were alive (risk
ratio, 0.83 [95% CI, 0.50e1.37]; risk difference: 2.0%
[95% CI, 7.5%e3.5%]; P ¼ 0.48). A favorable
neurologic outcome was observed in 18 patients
(7.6%) in the intervention group and 20 patients
(7.6%) in the placebo group at 30 days (risk ratio,
1.00 [95% CI, 0.55e1.83]; risk difference, 0.0% [95%
CI, 4.7%e4.9%]; P > 0.99). In patients with return
of spontaneous circulation, there were increased
rates of hyperglycemia and hypernatremia in the
treatment arm.
Limitations: Signiﬁcant fraction of eligible patients
did not participate in study limiting generalizability
and time to steroid/vasopressin dose varied significantly in patients. Trial was not powered to detect
differences in favorable neurologic outcomes so a
larger study is needed to determine if it is beneﬁcial
long term.
Bottom Line: This study suggests vasopressin and
methylprednisolone shortens arrest time and increases frequency of ROSC but we need more data
to determine whether it helps favorable neurologic
outcomes.
5. Topic: Toxicology
Question: Is haloperidol superior to ondansetron in
the management of cannabis hyperemesis?
Study: Ruberto AJ, et al. Intravenous Haloperidol
Versus Ondansetron for Cannabis Hyperemesis
Syndrome (HaVOC): A Randomized, Controlled
Trial. Ann Emerg Med. 2021.
Methods: Randomized, triple-blind crossover trial
of up to 3 treatment periods per subject from 2 academic emergency departments from 2017 to 2019.
30 patients were enrolled who received at least 1
treatment. They were randomized to either 0.05 mg/
kg haldol, 0.1 mg/kg haldol, or 8 mg ondansetron IV.
Primary outcome was a reduction in abdominal pain
and nausea in a 10 cm visual analog scale at 2 h post
treatment.
Results: Haldol at either dose was superior to
ondansetron for decreasing nausea and pain on a
visual analog scale (difference of 2.3 cm [95% conﬁdence interval 0.6e4.0 cm]) and shorter time to ED
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discharge (3.1 h vs 5.6 h a difference of 2.5 [95%
conﬁdence interval 0.1e5.0 h]).
Limitations: Small study of 30 patients which did
not achieve its enrollment goal and utilized a convenience sample.
Bottom Line: Although the study is underpowered,
the treatment effect was large and it may be
reasonable to utilize haloperidol as a ﬁrst line agent
in patients with cannabis hyperemesis. Results are
consistent with other published literature supporting the use of haloperidol for cannabis hyperemesis
syndrome and cyclical vomiting.
6. Topic: Infectious Disease
Question: Can a monoclonal antibody reduce the
chance of developing COVID 19 infection in at risk
individuals?
Study: O'Brien MP, et al. Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV
Antibody Combination to Prevent Covid-19. N Engl
J Med. 2021 Sep 23; 385 (13):1184e1195.
Methods: Prospective randomized double blind
controlled trial of 1550 patients who had inehome
contact with COVID positive persons, randomized
into placebo or subcutaneous REGEN-COV (casirivimab and imdevimab). Primary outcome was
development of symptomatic COVID infection at
day 28.
Results: Symptomatic SARS-CoV-2 infection developed in 11 of 753 participants in the REGEN-COV
group (1.5%) and in 59 of 752 participants in the
placebo group (7.8%) (relative risk reduction [1
minus the relative risk], 81.4%; P < 0.001). In weeks
2e4, a total of 2 of 753 participants in the REGENCOV group (0.3%) and 27 of 752 participants in the
placebo group (3.6%) had symptomatic SARS-CoV-2
infection (relative risk reduction, 92.6%). REGENCOV also prevented symptomatic and asymptomatic
infections overall (relative risk reduction, 66.4%).
Among symptomatic infected participants, the median time to resolution of symptoms was 2 weeks
shorter with REGEN-COV than with placebo (1.2
weeks and 3.2 weeks, respectively), and the duration
of a high viral load (>104 copies per milliliter) was
shorter (0.4 weeks and 1.3 weeks, respectively).
Limitations: Industry funded trial, possibly introducing bias. Additionally, excluded those with previous evidence of COVID 19 infection limiting
generalizability to those with previous COVID infections. Authors chose only to report on relative
risk reduction (common in industry sponsored trials), but the absolute risk reduction for symptomatic
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COVID infection was relatively low (6.3%) with a
number needed to treat of almost 17.
Bottom Line: In this well done study, subcutaneous
monoclonal antibodies appear to reduce the chance
of acquiring COVID 19 infection and its severity. It
is questionable whether the costs of treatment
justify widespread use for this purpose, but it may
have a place for prophylaxis in high-risk
individuals.
7. Topic: Covid-19
Question: How effective is the REGEN-COV
monoclonal antibody combination for preventing
hospitalization in outpatients with Covid-19?
Study: Weinreich DM, et al. REGN-COV2, a
Neutralizing Antibody Cocktail, in Outpatients with
Covid-19. N Engl J Med. 2021 Jan 21; 384
(3):238e251. doi: 10.1056/NEJMoa2035002. Epub
2020 Dec 17.
Methods: This is the phase 3 portion of a trial
studying the effectiveness of combination infusion
therapy with casirivimab and imdevimab when
given to outpatients with Covid-19 who have risk
factors for severe disease. Patients were assigned to
varying doses of antibodies and were followed for
29 days. Endpoints were hospitalization or death.
Viral load was also measured and safety was
assessed.
Results: Hospitalization or death from any cause
occurred in a total of 25 of 2091 (1.1%) patients in the
group receiving REGEN-COV antibodies and 86 of
2089 patients receiving placebo (4.1%) for a relative
risk reduction of 71.0% and absolute risk reduction
of about 3%. Number needed to treat was 34 to
prevent hospitalization or death. Only 5 deaths
occurred, two in the placebo group and one in the
REGEN-COV group. There were few adverse events
generally, with more adverse events recorded in the
placebo than intervention group. There did not
appear to be a signiﬁcant difference in efﬁcacy between the various doses.
Limitations: The study was industry sponsored,
which must prompt additional scrutiny. Relatively
few deaths occurred, limiting the ability to draw
conclusions as to mortality beneﬁt. Trial enrollment
ended in January of 2021, before the Delta variant
was predominant. It remains to be seen if this drug
cocktail will continue to be effective against new
variants.
Bottom Line: The REGEN-COV drug cocktail containing casirivimab and imdevimab appears to be at
least moderately effective in preventing hospitalizations in patients with risk factors for severe Covid
illness. Given the paucity of effective treatments for
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outpatients with Covid, referral for the antibody
infusion is probably warranted.
8. Topic: Pediatrics/Trauma
Question: What is the prevalence of serious injury
in pediatric patients presenting with blunt trauma
from a bicycle handlebar impact?
Study: Vandewalle RJ, Barker SJ, Raymond JL,
Brown BP, Rouse TM. Pediatric Handlebar Injuries:
More Than Meets the Abdomen. Pediatr Emerg
Care. 2021 Sep 1; 37 (9):e517-e523.
Methods: Retrospective chart review of pediatric
bicycle accidents from a trauma registry over an 8
year period at a single tertiary pediatric center
(Indiana Health). Injuries were classiﬁed as “handlebar” or “non-handlebar” and injuries were classiﬁed by body zone (abdomen, thorax, etc.) and type
(hollow-viscus, solid organ, soft-tissue, etc.). Injury
severity and need for operative intervention or a
procedure was recorded.
Results: 385 patients met inclusion criteria. Mean age
was approximately 9 years. Handlebar injuries were
involved in 27.9% of bicycle related trauma cases.
34.6% of these patients had a solid organ injury and
9.3% had a hollow-viscus injury. 21.6% of handlebar
injury cases required surgery and/or a procedure
such as embolization. Most patients presented with
both physical ﬁndings and a history consistent with a
handlebar injury but some signiﬁcant injuries were
identiﬁed on history alone. Two patients with no
evidence of bowel injury on initial CT scan required
laparotomy for bowel perforation after developing
peritonitis less than 12 h after injury. CT scans in
some cases of serious hollow-viscus injury were
negative or showed only pericolic/pelvic free ﬂuid.
Limitations: Retrospective data obtained by chart
review, so some cases may have been missed and
documentation may have been incomplete. Data is
from a large referral hospital, so the patient population likely reﬂects a sicker group than that seen in
the typical emergency department.
Bottom Line: Be sure to perform a careful physical
examination and history when evaluating pediatric
trauma involving bicycle handlebars and bicycle
accidents in general. Have a low threshold to obtain
imaging and lab studies and transfer these patients
to a pediatric trauma center for surgical evaluation
and/or observation.
9. Topic: Neurology
Question: Does IV TPA improve outcomes when
given before endovascular procedures for large
vessel occlusions in stroke?
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Study: LeCouffe N, et al. A Randomized Trial of
Intravenous Alteplase before Endovascular Treatment for Stroke. N Engl J Med. 2021 Nov 11; 385
(20):1833e1844. doi: 10.1056/NEJMoa2107727.
Methods: Open label, multicenter controlled trial of
patients in Europe with stroke who were candidates
for both TPA and endovascular repair (EVT). They
were randomized to TPA þ endovascular or endovascular alone. Primary outcome was functional
outcomes on modiﬁed Rankin scale at 90 days.
Secondary outcomes include mortality and symptomatic intracerebral hemorrhage.
Results: Median score on the modiﬁed Rankin scale
at 90 days was 3 (interquartile range, 2 to 5) with
EVT and 2 (interquartile range, 2 to 5) with alteplase
plus EVT. The adjusted common odds ratio was 0.84
(95% conﬁdence interval [CI], 0.62 to 1.15; P ¼ 0.28),
which showed neither superiority nor noninferiority
of EVT alone. Mortality was 20.5% with EVT alone
and 15.8% with alteplase plus EVT (adjusted odds
ratio, 1.39; 95% CI, 0.84 to 2.30). Symptomatic
intracerebral hemorrhage occurred in 5.9% and
5.3% of the patients in the respective groups
(adjusted odds ratio, 1.30; 95% CI, 0.60 to 2.81).
Limitations: The study only used those patients
presenting to an EVT center so not generalizable to
non primary stroke centers. There was no blinding
and there were also some differences in the groups
(occlusion location, presence of atrial ﬁbrillation)
that may have skewed results.
Bottom Line: In this well done trial, TPA does not
appear to add much to the care of large vessel occlusion patients who are also receiving endovascular therapy in patients presenting to a primary
EVT center.
10. Topic: Infectious Disease
Question: What is the resistance rate to 3rd generation cephalosporins in patients with febrile UTIs
presenting to the emergency department?
Study: Mark D, et al.Third-Generation Cephalosporin
Resistance and Associated Discordant Antibiotic
Treatment in Emergency Department Febrile Urinary
Tract Infections. Ann Emerg Med. 2021 Sep; 78
(3):357e369. doi: 10.1016/j.annemergmed.2021.01.003.
Epub 2021 Mar 27.
Methods: Retrospective cohort study of all adults
with febrile UTI at 21 hospitals in the Kaiser system
in California between Jan 2017eJune 2019. Inclusion
criteria included fever, admitting diagnosis of UTI,
pyelonephritis, or sepsis and urine culture
>100,000 CFU of a EKP species (E.coli, K.pneumoniae, P.mirabilis). Primary outcome was discordant
antibiotic
treatment
when
compared
to
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antimicrobial susceptibility testing. Secondary outcomes were hospital length of stay and 90 day
mortality.
Results: 4107 patients were included. Of these patients, 12.9% had EKP-resistant to 3rd generation
cephalosporins. There was a 63% discordant antibiotic therapy with susceptibility testing in case
groups (OR 21.0; 95% CI 16.9 to 26.0). Hospital stay
was longer in EKP-resistant organism cases with an
adjusted mean difference of 29.7 h (95%CI 19.0 to
40.4) and 90 day mortality was higher 12% vs 8%
(aOR 1.56; 95% CI 1.07 to 2.28). 89% of resistant
isolates were susceptible to piperacillin/tazobactam
and 100% of isolates were susceptible to
meropenem.
Limitations: Retrospective study. It was limited to
California, which may have a unique resistance
pattern not seen elsewhere and limits generalizability. They did not comment on asymptomatic
bacteriuria which could have made up some of the
cases and they did not account for catheter associated infections.
Bottom Line: A signiﬁcant fraction of admitted patients with febrile UTI have resistance to 3rd generation cephalosporins, suggesting we should take
this into account along with our local resistance
patterns when determining the best agent for this
patient population. It may be reasonable to choose
meropenem or a similar extremely broad spectrum
choice in the sickest patients, especially if risk factors for drug resistance are present.
11. Topic: Toxicology/Addiction Medicine
Question: Among discharged patients treated for
alcohol withdrawal, does phenobarbital lead to
fewer return ED visits than benzodiazepines?
Study: Lebin JA, et al. Return Encounters in Emergency Department Patients Treated with Phenobarbital Versus Benzodiazepines for Alcohol
Withdrawal. J Med Toxicol. 2021 Oct 25. doi:
10.1007/s13181-021-00863-2. Epub ahead of print.
Methods: Retrospective chart review of a single academic medical center. Primary outcome was any
return ED visit within 3 days. Secondary outcomes
were any return ED visit within 3e7 days and evidence of survival after discharge. Return ED visits
and survival were identiﬁed via Care Everywhere
(i.e. although the study was single-center, charts
from throughout the local region were reviewed for
return visits).
Results: 470 patients met inclusion criteria (discharged with diagnosis of alcohol withdrawal
and received treatment in the ED for same). 133
were treated with phenobarbital, 235 with
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benzodiazepines, 102 with a combination of both.
Overall, populations were similar. Patients treated
with phenobarbital had substantially lower risk of
return ED visit within 3 days (10% versus 25% for
benzodiazepines, p ¼ 0.001), although this difference was not statistically signiﬁcant between 3 and 7
days (6% versus 10% for benzodiazepines, p ¼ 0.36).
Patients treated with phenobarbital received substantially more lorazepam equivalents than patients
treated with benzodiazepines (26 mg vs. 6 mg,
p < 0.001). Survival was not signiﬁcantly different
between the two groups (97.7% in phenobarbital
group, 94.5% in benzodiazepine group, 94% in
combination group, p ¼ 0.12).
Limitations: Single center, unable to assess whether
discharge medications were used or ﬁlled, survival
statistics are secondary outcome and hypothesisgenerating rather than hypothesis-conﬁrming. Patients not re-presenting to a local Care Everywhere
participating center may have been lost to followup.
Bottom Line: Patients not requiring inpatient management treated for alcohol withdrawal with
phenobarbital had fewer return ED visits, received
substantially more lorazepam equivalents, and had
similar mortality to patients treated with benzodiazepines. Phenobarbital treatment appears to be
safe and may reduce ED bouncebacks. The increase
in equivalent dosing was hypothesized as resulting
from clinician and nursing discomfort with
diverging from ‘standard’ doses of benzodiazepines
when larger doses are necessary, as is also seen
when comparing morphine and hydromorphone
dosing. (For a non-academic review of phenobarbital treatment for alcohol withdrawal, see
PulmCrit).
12. Topic: Ethics
Question: How does the presence of law enforcement impact emergency care?
Study: Janeway HH, et al. An Ethical, Legal, and
Structural Framework for Law Enforcement in the
Emergency Department. Ann Emerg Med. 2021 Oct
27:S0196-0644 (21)00796-4. doi: 10.1016/j.annemergmed.2021.08.009. Epub ahead of print. Editorial
in review of Harada MY, et al. Policed Patients: How
the Presence of Law Enforcement in the Emergency
Department Impacts Medical Care. Ann Emerg
Med. 2021 Jul 28:S0196-0644 (21)00380-2. doi:
10.1016/j.annemergmed.2021.04.039. Epub ahead of
print.
Methods: Qualitative semi-structured interviews of
emergency physicians using snowball sampling (a
recruitment technique in which research participants
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are asked to assist researchers in identifying other
potential subjects) recruited from 3 large, public
hospitals serving largely lower socioeconomic status
patients. Themes were abstracted and categorized
using a grounded theory approach.
Results: 20 full-time emergency physicians were
interviewed across a range of ages, ethnicities, genders, and experience levels. The majority considered
law enforcement to have a mixed, largely negative
but sometimes positive impact on clinical care. Positive experiences with law enforcement included
increased sense of safety and receiving helpful prehospital information. Negative experiences included
direct impediments to critical and other emergency
care, breaches of conﬁdentiality and patient privacy,
loss of patient trust, barriers to patients presenting
due to fear of police, physicians feeling intimidated
by police, lack of understanding of legal and hospital
policy rules and rights for patients and staff, conﬂation of medical staff with law enforcement, and
physicians being threatened with arrest when not
complying with police demands.
Limitations: Qualitative survey, hypothesis-generating rather than hypothesis-conﬁrming, no quantitative analysis, snowball sampling increases risk of
bias (speciﬁcally selection bias), no evaluation of
patient or law enforcement perspectives, single state
(California).
Bottom Line: The presence of law enforcement ofﬁcers
can conﬂict with clinical and patient-centered objectives. Emergency physicians may tolerate or support
police over patient interests, leading to breaches in
conﬁdentiality, poor rapport, and even obstruction of
critical procedures such as intubation and acute
resuscitation. Complicity with police demands has the
potential to undermine established principles of
medical ethics. Simultaneously, police can be helpful
in providing information and responding to violence
in the ED. A new framework to help clinicians navigate
the conﬂicts between law enforcement objectives and
the principles of patient-centered care is needed.
13. Topic: Infectious Disease, Resuscitation
Question: Does the Surviving Sepsis Campaign
(SSC) hour-1 bundle decrease mortality in septic
adults at 28 days compared to the hour-3 bundle?
Study: Prachanukool T, et al. The 28-Day Mortality
Outcome of the Complete Hour-1 Sepsis Bundle in
the Emergency Department. Shock. 2021; 56
(6):969e974. doi:10.1097/SHK.0000000000001815.
Methods: As we are all well aware, the SSC sepsis
bundle consists of 1) lactate measurement, 2) blood
cultures prior to antibiotics, 3) broad-spectrum antibiotics, 4) 30 mL/kg crystalloid for hypotension or
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lactate >4, and 5) vasopressors for MAP <65 after
ﬂuid bolus. In 2018, SSC began recommending that
this occur after 1 h rather than the previous 3 h. In
this prospective, single academic tertiary care center
cohort study in Thailand from MarcheJuly 2019, 593
adult patients were enrolled and divided into cohorts based on whether these targets were met
under 1 h per SSC guidelines or under 3 h. Patients
with a DNR, who were transferred, were treated
prior to arrival, or had cardiac arrest were excluded.
Results: Even though the hour-3 patients were
sicker, there was no difference in 28 day mortality
between the cohorts. Additionally, there was no
difference in need for vasopressors or incidence of
delayed septic shock, even in subgroup analyses.
Patients in the hour-1 cohort were slightly more
likely to be admitted to the ICU.
Limitations: Single center, cohorts may not truly be
comparable, nonrandomized (like all cohort
studies), Thai population rather than our American
population, few (1.9%) had septic shock.
Bottom Line: Giving the SSC sepsis bundle under
1 h did not change patient-centered outcomes
compared to under 3 h in this population of septic
patients, most of whom did not have septic shock.
14. Topic: Addiction Medicine
Question: How often are buprenorphine or
naloxone prescribed after opioid overdose in
American hospitals, and how does this compare to
prescriptions of epinephrine after anaphylaxis?
Study: Chua KP, et al. Naloxone and Buprenorphine
Prescribing Following US Emergency Department
Visits for Suspected Opioid Overdose: August 2019
to April 2021 [published online ahead of print, 2021
Nov 18]. Ann Emerg Med. 2021; S0196-0644 (21)
01349-4. doi:10.1016/j.annemergmed.2021.10.005.
Methods: Retrospective chart review of emergency
department visits via a national database including
5800 hospitals and 70,000 pharmacies (~93% of
dispensed prescriptions across the United States)
from August 2019eApril 2021 by searching for any
visit containing a CPT code for opioid overdose or
anaphylaxis. 148,966 encounters for opioid overdose
and 43,712 for anaphylaxis were included.
Results: Naloxone was prescribed after 7.4% of
opioid overdose visits and buprenorphine after
8.5%, compared to epinephrine being prescribed
after 48.9% of anaphylaxis visits. Emergency
department visits for opioid overdose increased by
23.6% after the COVID-19 pandemic began, while
overall volume decreased.
Limitations: The database used appears to overrepresent commercially-insured patients and
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underrepresent Medicaid and uninsured patients,
although this likely means these medications are
prescribed even less frequently than found here.
Multiple visits per day were missed due to database
limitations. Fatal overdoses, although likely few,
were not able to be excluded due to database limitations. CPT codes are insensitive to identify cases,
although they are speciﬁc, and so many cases may
have been missed. Paper prescriptions were missed.
Bottom Line: Emergency physicians prescribe
naloxone or buprenorphine to fewer than 1 in 10
appropriate patients, a strikingly small number
compared to epinephrine after anaphylaxis. Especially as opioid overdoses continue to rise, we should
try to induce buprenorphine or prescribe naloxone to
patients as often as possible. (To address one common concern, naloxone prescription is not associated
with increased opioid usage, as conﬁrmed in a recent
publication by Tse et al. in Int J Drug Pol.)
15. Topic: Pain Management
Question: Is a 15 mg dose of ketorolac (Toradol)
given intramuscularly (IM) non-inferior to a 60 mg
dose when given for acute musculoskeletal (MSK)
pain?
Study: Turner NJ, et al. Comparing two doses of
intramuscular ketorolac for treatment of acute
musculoskeletal pain in a military emergency
department. Am J Emerg Med. 2021 Dec; 50:142e147.
Methods: Single-blinded, randomized controlled,
non-inferiority trial of adults presenting to an ED
with a chief complaint of acute MSK pain. Patients
were randomized to receive a 15 mg or a 60 mg IM
ketorolac dose. The primary outcome was the mean
difference of change in pain from baseline at one
hour between the two groups as reported on a 100mm (mm) visual analog scale. Only relatively low
acuity (ESI 4 or 5) patients were included.
Results: 110 patients were randomized. The mean
difference in pain score at one hour was 0.2 mm [95%
CI-85-8.7). There were no major adverse effects reported, although patients receiving the higher dose
reported more burning at the injection site.
Limitations: Conducted at a department of defense
facility/single center. Patient population may not be
completely representative of those seen at some
emergency departments. High acuity complaints
were excluded. Effects were followed only for one
hour so no determination of efﬁcacy or side effects
beyond this point can be measured.
Bottom Line: For adult patients presenting with
acute MSK pain, 15 mg of IM ketorolac was noninferior to a 60 mg dose when outcomes were
measured at one hour. The 60 mg IM dose dogma
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seems to be dying hard (still recommended by
UpToDate!). Results of this study are consistent with
other recent published studies on this topic. We
should be limiting the dose of ketorolac for acute
MSK pain to 15 mg whether given IV or IM.
16. Topic:
(VTE)

COVID/Venous

Thromboembolism

Question: Is there a difference in the risk and
prevalence of thrombosis in patients undergoing
testing for VTE with conﬁrmed COVID infection
when compared to patients without COVID?
Study: Wretborn J, et al. Risk of venous thromboembolism in a Swedish healthcare system during
the COVID-19 pandemic: A retrospective crosssectional study. J Am Coll Emerg Physicians Open.
2021 Sep 1; 2 (5):e12530.
Methods: Retrospective observational study of adult
patients in Sweden. Patients were included if they
had testing for VTE performed. Groups were separated into COVID positive or negative based on
documented PCR results in the 30 days prior to or
after testing. The outcome was diagnosis of VTE by
ultrasound or CTPA. Logistic regression was used to
investigate the risks for VTE by COVID-19 status
and the risk of VTE was also compared to risk
during the pre-COVID timeframe (2015e2019).
Results: A total of 8702 tests for VTE were included
in the analysis, 1398 of which had been performed in
2020. COVID infection was conﬁrmed in 88 cases, 14
of which were positive for VTE. There was no signiﬁcant difference in the prevalence of VTEs between the conﬁrmed SARS-CoV-2epositive, SARSCoV-2enegative, or untested groups (15.9%, 17.6%,
and 15.7% in each group, respectively, P ¼ 0.85).
There was no signiﬁcant difference in the overall
rate prevalence of positive VTE tests in the 2020
cohort when compared to the 2015e2019 cohort.
There was a higher prevalence of VTE in COVID
positive patients admitted to the ICU.
Limitations: This is observational data from a single
county in Sweden. Patients were only included if
VTE testing was performed and COVID status was
not available for a large number of patients. Some
patients may have tested positive for VTE outside
the healthcare system, and could have been missed.
Bottom Line: These results are consistent with other
recent studies suggesting that COVID is not a strong
independent risk factor for VTE, at least in outpatients. Traditional risk stratiﬁcation methods for
VTE appear to be holding up well when applied to
ambulatory patients with COVID.

https://scholar.rochesterregional.org/advances/vol2/iss1/5
DOI: 10.53785/2769-2779.1089

17. Topic: Cardiac Arrest
Question: Does routine use of calcium in out of
hospital cardiac arrest affect clinical outcomes?
Study: Vallentin MF et al. Effect of Intravenous or
Intraosseous Calcium vs Saline on Return of Spontaneous Circulation in Adults With Out-of-Hospital
Cardiac Arrest: A Randomized Clinical Trial. JAMA.
2021 Dec 14; 326 (22):2268e2276. https://doi.org/10.
1001/jama.2021.20929.
Methods: Double-blind, prospective randomized
trial of 397 out of hospital cardiac arrest patients
randomized to either intraosseous calcium chloride
or normal saline along with routine cardiac arrest
protocols. Primary outcome was sustained return of
spontaneous circulation (ROSC) and secondary
outcomes were survival and favorable neurologic
outcome at 30 and 90 days.
Results: Trial was stopped early at an interim
analysis due to harm in the calcium group. 391 were
included in the analysis. 37 patients in the calcium
group (19%) had sustained ROSC compared with 53
(27%) in the saline group [risk ratio 0.72 (95% CI 0.49
to 1.03). At 30 days, 10 patients (5.2%) in the calcium
group and 18 patients (9.1%) in the saline group
were alive (risk ratio, 0.57 [95% CI, 0.27 to 1.18], A
favorable neurological outcome at 30 days was
observed in 7 patients (3.6%) in the calcium group
and in 15 patients (7.6%) in the saline group (risk
ratio, 0.48 [95% CI, 0.20 to 1.12].
Limitations: The trial did not reach its pre-planned
size, it was stopped early, CI are wide and it is
possible the results are due to random chance.
Bottom Line: It does not appear in this study that
addition of calcium chloride is superior to saline,
and may actually be harmful, but larger studies are
needed to conﬁrm the effects.
18. Topic: Medical Technology
Question: Can a patient's pulse be measured with
non-contact methods?
Study: Caspar M, et al. Contact-Free Monitoring of
Pulse Rate For Triage of Patients Presenting to the
Emergency Department. J Emerg Med. 2021 Aug
30:S0736-4679 (21)00543-6. https://doi.org/10.1016/j.
jemermed.2021.07.005. Epub ahead of print.
Methods: Convenience sample of 446 patients presenting to a single ED. Pulse was estimated with a
camera-based
prototype
application,
which
measured subtle differences in patient skin that
varied with pulse rate and was compared to pulse
oximetry for correlation.
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Results: In the 446 patients, the correlation between
CBPA and pulse oximetry in measuring PR was
0.939 (95% conﬁdence interval [CI] 0.927e0.949).
Limitations: Single center convenience sample,
possibly introducing bias and potentially limiting
generalizability. It is unclear if it reliably measures
the pulse in arrhythmias as the comparison was
pulse oximetry measurements which are notoriously unreliable with arrhythmias. This was performed in Switzerland with a predominantly white
population, so may not be generalizable to all skin
types.
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Bottom Line: Contact free pulse measurement
seems to be an effective method of pulse measurement, at least in a predominantly white population.
More research is needed if it is reliable in all patient
skin types. If so, it could be an easy, noninvasive,
more sanitary way for us to monitor our patients in
the ED.
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